{"id":68895,"date":"2025-07-17T03:47:24","date_gmt":"2025-07-17T03:47:24","guid":{"rendered":"https:\/\/www.europesays.com\/us\/68895\/"},"modified":"2025-07-17T03:47:24","modified_gmt":"2025-07-17T03:47:24","slug":"sarepta-therapeutics-lays-off-one-third-of-workforce-in-drastic-cost-cutting-move","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/us\/68895\/","title":{"rendered":"Sarepta Therapeutics lays off one-third of workforce in drastic cost-cutting move"},"content":{"rendered":"<p class=\"author-bio\">Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast <a href=\"https:\/\/www.statnews.com\/category\/readout-loud\/\" target=\"_blank\" rel=\"noopener\">The Readout Loud<\/a> and author of the newsletter <a href=\"https:\/\/www.statnews.com\/signup\/scorecard\/\" target=\"_blank\" rel=\"noopener\">Adam\u2019s Biotech Scorecard.<\/a> You can reach Adam on Signal at stataf.54.<\/p>\n<p>Sarepta Therapeutics laid off more than one-third of its workforce, or approximately 500 employees, the company announced Wednesday \u2014 a drastic cost-cutting move following <a href=\"https:\/\/www.statnews.com\/2025\/06\/15\/duchenne-sarepta-gene-therapy-elevidys-patient-death\/\" target=\"_blank\" rel=\"noopener\">the deaths of two teenagers<\/a> that forced the company to restrict usage of its gene therapy for Duchenne muscular dystrophy.<\/p>\n<p>Alongside the cuts, the company also announced it was shifting much of its research, including pausing work on several gene therapies it had in development for limb-girdle muscular dystrophies, a collection of rarer and generally slower-moving diseases. The company said the move will save the company around $400 million per year, lower operating expenses, and boost cash flow sufficient to maintain access to an existing loan agreement.<\/p>\n<p>Three of Sarepta\u2019s top executives, including its No. 2 executive Ian Estepan, received promotions and salary increases, according to a filing with the Securities and Exchange Commission that accompanied the company\u2019s announcement of employee layoffs. <\/p>\n<p class=\"restricted-text\">STAT+ Exclusive Story<\/p>\n<p class=\"restricted-login\">Already have an account? <a href=\"https:\/\/www.statnews.com\/login\/\" data-stat-login=\"\" data-stat-paywall-cta=\"breaker login cta\" target=\"_blank\" rel=\"noopener\">Log in<\/a><\/p>\n<p>\t\t\t<img decoding=\"async\" class=\"restricted-content-breaker-bg\" src=\"https:\/\/www.europesays.com\/us\/wp-content\/uploads\/2025\/06\/stat-plus-breaker-bg.png\" alt=\"STAT+\"\/><\/p>\n<p>\t\t\t\t\t<a href=\"https:\/\/www.statnews.com\/stat-plus\/\" target=\"_blank\" rel=\"noopener\"><br \/>\n\t\t\t\t\t\t<img decoding=\"async\" class=\"stat-plus-logo\" src=\"https:\/\/www.statnews.com\/wp-content\/themes\/stat\/images\/stat-plus-logo-white.svg\" alt=\"STAT+\"\/><br \/>\n\t\t\t\t\t<\/a><\/p>\n<p>\t\t\t\tThis article is exclusive to STAT+ subscribers<br \/>\n\t\t\t\tUnlock this article \u2014 plus daily coverage and analysis of the biotech sector \u2014 by subscribing to STAT+.<\/p>\n<p class=\"restricted-content-breaker-wrapper-cta mobile\">Already have an account? <a href=\"https:\/\/www.statnews.com\/login\/\" data-stat-login=\"\" data-stat-paywall-cta=\"breaker login cta mobile\" target=\"_blank\" rel=\"noopener\">Log in<\/a><\/p>\n<p>\t\t\t\t\t\tIndividual plans<\/p>\n<p>\t\t\t\t\t\tGroup plans<\/p>\n<p>\t\t\t\t<a href=\"https:\/\/www.statnews.com\/stat-plus\/\" class=\"stat-button view-all\" data-stat-paywall-cta=\"breaker view all plans\" aria-label=\"View All Plans\" target=\"_blank\" rel=\"noopener\">View All Plans<\/a><\/p>\n<p class=\"restricted-content-text\">\n\t\t\t\t\t\tTo read the rest of this story subscribe to STAT+.\t\t\t\t\t<\/p>\n<p>\t\t\t\t\t<a href=\"https:\/\/www.statnews.com\/stat-plus\/\" class=\"stat-button restricted-button\" data-stat-paywall-cta=\"breaker subscribe cta 1\" target=\"_blank\" rel=\"noopener\">Subscribe<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall&hellip;\n","protected":false},"author":3,"featured_media":68896,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[6],"tags":[150,64,3014,154,67,132,68],"class_list":{"0":"post-68895","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-business","8":"tag-biotechnology","9":"tag-business","10":"tag-rare-diseases","11":"tag-stat","12":"tag-united-states","13":"tag-unitedstates","14":"tag-us"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@us\/114866529451102681","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/68895","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/comments?post=68895"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/68895\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media\/68896"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media?parent=68895"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/categories?post=68895"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/tags?post=68895"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}